OAM
ANIP icon

Oppenheimer Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Oppenheimer Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4,113
Closed -$204K – 1667
2017
Q1 		$204K Buy
+4,113
New +$231K 0.01% 1042

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Oppenheimer Asset Management's ANIP Position: Q2 2017 in Review

Oppenheimer Asset Management sold out of ANI Pharmaceuticals (ANIP) in Q2 2017, closing a stake of 4,113 shares — an estimated $204K sold.

Oppenheimer Asset Management first reported a position in ANIP in Q1 2017 and held it in 1 quarter. The position peaked at $204K in Q1 2017. 151 funds tracked by Wall St. Rank hold ANIP as of Q2 2017.

  • Oppenheimer Asset Management reported no remaining ANI Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Oppenheimer Asset Management sold 4,113 ANI Pharmaceuticals shares in Q2 2017, an estimated $204K.
  • Oppenheimer Asset Management first reported a position in ANI Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Oppenheimer Asset Management's ANI Pharmaceuticals position peaked at $204K in Q1 2017.
  • 151 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2017.

Based on Oppenheimer Asset Management's 13F filing for Q2 2017, filed 9 Aug 2017.